Patents by Inventor Shinichi Hasako

Shinichi Hasako has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SELECTIVE INHIBITOR OF EXON 20 INSERTION MUTANT EGFR
    Publication number: 20240148734
    Abstract: An antitumor agent comprising a compound selected from the group consisting of Compounds A to D described in the specification, or a salt thereof, for treating a malignant tumor patient expressing EGFR having exon 20 insertion mutation.
    Type: Application
    Filed: November 17, 2023
    Publication date: May 9, 2024
    Applicant: Taiho Pharmaceutical Co., Ltd.
    Inventors: Kazutaka Miyadera, Yoshimi Aoyagi, Shinichi Hasako
  • Selective inhibitor of exon 20 insertion mutant EGFR
    Patent number: 11857513
    Abstract: An antitumor agent comprising a compound selected from the group consisting of Compounds A to D described in the specification, or a salt thereof, for treating a malignant tumor patient expressing EGFR having exon 20 insertion mutation.
    Type: Grant
    Filed: October 31, 2017
    Date of Patent: January 2, 2024
    Assignee: Taiho Pharmaceutical Co., Ltd.
    Inventors: Kazutaka Miyadera, Yoshimi Aoyagi, Shinichi Hasako
  • Exon 18 and/or exon 21 mutant EGFR selective inhibitor
    Patent number: 11701359
    Abstract: An antitumor agent for treating a malignant tumor patient expressing EGFR having at least one mutation selected from the group consisting of G719X mutation of exon 18, E709X mutation of exon 18, and L861X mutation of exon 21, wherein X represents an arbitrary amino-acid residue, the antitumor agent comprising (S)-N-(4-amino-6-methyl-5-(quinolin-3-yl)-8,9-dihydropyrimido[5,4-b]indolizin-8-yl)acrylamide or a salt thereof.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: July 18, 2023
    Assignee: Taiho Pharmaceutical Co., Ltd.
    Inventors: Naomi Abe, Shinichi Hasako
  • L718 AND/OR L792 MUTANT TREATMENT-RESISTANT EGFR INHIBITOR
    Publication number: 20220072000
    Abstract: The present invention provides an antitumor agent for treating a malignant tumor patient expressing EGFR having at least one mutation selected from the group consisting of L718X mutation in exon 18 and L792X mutation in exon 20, wherein X represents an arbitrary amino-acid residue, the antitumor agent comprising (S)-N-(4-amino-6-methyl-5-(quinolin-3-yl)-8,9-dihydropyrimido[5,4-b]indolizin-8-yl)acrylamide (Compound (A)) or a salt thereof.
    Type: Application
    Filed: December 27, 2019
    Publication date: March 10, 2022
    Inventors: Shinichi HASAKO, Takao UNO
  • EXON 18 AND/OR EXON 21 MUTANT EGFR SELECTIVE INHIBITOR
    Publication number: 20200253975
    Abstract: An antitumor agent for treating a malignant tumor patient expressing EGFR having at least one mutation selected from the group consisting of G719X mutation of exon 18, E709X mutation of exon 18, and L861X mutation of exon 21, wherein X represents an arbitrary amino-acid residue, the antitumor agent comprising (S)-N-(4-amino-6-methyl-5-(quinolin-3-yl)-8,9-dihydropyrimido[5,4-b]indolizin-8-yl)acrylamide or a salt thereof.
    Type: Application
    Filed: August 31, 2018
    Publication date: August 13, 2020
    Inventors: Naomi Abe, Shinichi Hasako
  • SELECTIVE INHIBITOR OF EXON 20 INSERTION MUTANT EGFR
    Publication number: 20190262345
    Abstract: An antitumor agent comprising a compound selected from the group consisting of Compounds A to D described in the specification, or a salt thereof, for treating a malignant tumor patient expressing EGFR having exon 20 insertion mutation.
    Type: Application
    Filed: October 31, 2017
    Publication date: August 29, 2019
    Inventors: Kazutaka Miyadera, Yoshimi Aoyagi, Shinichi Hasako
  • Gene/protein marker for prediction or diagnosis of pharmacological efficacy of aurora a inhibitor
    Publication number: 20100022404
    Abstract: [PROBLEMS] To provide: a gene marker or a protein marker for detecting whether or not an Aurora A inhibitor acts in a living body in an Aurora A-specific manner when the Aurora A inhibitor is administered to the living body; and a method for predicting or diagnosing the pharmacological efficacy of an Aurora A inhibitor by using the gene marker or the protein marker [MEANS FOR SOLVING PROBLEMS] A gene/protein marker for use in the prediction or diagnosis of the pharmacological efficacy of an Aurora A inhibitor, wherein the gene is a gene selected from the group consisting of Aurora B, Histone H3, BIRC5, PRC1, DLG7, TACC3 and KNTC2 or a gene having substantially the same function as that of the gene; and a method for predicting or diagnosing the pharmacological efficacy of an Aurora A inhibitor by using the gene/protein marker.
    Type: Application
    Filed: October 5, 2007
    Publication date: January 28, 2010
    Inventors: Shinichi Hasako, Koji Ichikawa, Hideto Kotani, Satomi Miki, Katsuyoshi Miyama, Toshiyasu Shimomura, Kazuhiko Takahashi, Kazunori Yamanaka